S&P 500   4,616.63 (+1.09%)
DOW   34,727.88 (+0.71%)
QQQ   397.97 (+1.05%)
AAPL   167.70 (+1.45%)
MSFT   336.62 (+1.82%)
FB   327.57 (+0.96%)
GOOGL   2,878.66 (+1.43%)
AMZN   3,537.18 (+0.86%)
TSLA   1,163.52 (+1.64%)
NVDA   329.64 (+0.88%)
BABA   127.59 (+0.05%)
NIO   39.78 (+1.66%)
CGC   10.71 (+0.00%)
AMD   158.86 (+0.31%)
GE   96.24 (+1.32%)
MU   86.69 (+3.20%)
T   22.92 (+0.39%)
F   19.87 (+3.54%)
DIS   147.23 (+1.61%)
ACB   6.43 (+0.16%)
PFE   52.98 (-1.40%)
AMC   34.52 (+1.71%)
BA   198.45 (+0.30%)
S&P 500   4,616.63 (+1.09%)
DOW   34,727.88 (+0.71%)
QQQ   397.97 (+1.05%)
AAPL   167.70 (+1.45%)
MSFT   336.62 (+1.82%)
FB   327.57 (+0.96%)
GOOGL   2,878.66 (+1.43%)
AMZN   3,537.18 (+0.86%)
TSLA   1,163.52 (+1.64%)
NVDA   329.64 (+0.88%)
BABA   127.59 (+0.05%)
NIO   39.78 (+1.66%)
CGC   10.71 (+0.00%)
AMD   158.86 (+0.31%)
GE   96.24 (+1.32%)
MU   86.69 (+3.20%)
T   22.92 (+0.39%)
F   19.87 (+3.54%)
DIS   147.23 (+1.61%)
ACB   6.43 (+0.16%)
PFE   52.98 (-1.40%)
AMC   34.52 (+1.71%)
BA   198.45 (+0.30%)
S&P 500   4,616.63 (+1.09%)
DOW   34,727.88 (+0.71%)
QQQ   397.97 (+1.05%)
AAPL   167.70 (+1.45%)
MSFT   336.62 (+1.82%)
FB   327.57 (+0.96%)
GOOGL   2,878.66 (+1.43%)
AMZN   3,537.18 (+0.86%)
TSLA   1,163.52 (+1.64%)
NVDA   329.64 (+0.88%)
BABA   127.59 (+0.05%)
NIO   39.78 (+1.66%)
CGC   10.71 (+0.00%)
AMD   158.86 (+0.31%)
GE   96.24 (+1.32%)
MU   86.69 (+3.20%)
T   22.92 (+0.39%)
F   19.87 (+3.54%)
DIS   147.23 (+1.61%)
ACB   6.43 (+0.16%)
PFE   52.98 (-1.40%)
AMC   34.52 (+1.71%)
BA   198.45 (+0.30%)
S&P 500   4,616.63 (+1.09%)
DOW   34,727.88 (+0.71%)
QQQ   397.97 (+1.05%)
AAPL   167.70 (+1.45%)
MSFT   336.62 (+1.82%)
FB   327.57 (+0.96%)
GOOGL   2,878.66 (+1.43%)
AMZN   3,537.18 (+0.86%)
TSLA   1,163.52 (+1.64%)
NVDA   329.64 (+0.88%)
BABA   127.59 (+0.05%)
NIO   39.78 (+1.66%)
CGC   10.71 (+0.00%)
AMD   158.86 (+0.31%)
GE   96.24 (+1.32%)
MU   86.69 (+3.20%)
T   22.92 (+0.39%)
F   19.87 (+3.54%)
DIS   147.23 (+1.61%)
ACB   6.43 (+0.16%)
PFE   52.98 (-1.40%)
AMC   34.52 (+1.71%)
BA   198.45 (+0.30%)
NASDAQ:AVDL

Avadel Pharmaceuticals Stock Forecast, Price & News

$8.93
-0.03 (-0.33%)
(As of 12/1/2021 12:00 AM ET)
Add
Compare
Today's Range
$8.93
$9.07
50-Day Range
$7.89
$11.18
52-Week Range
$6.03
$11.59
Volume
404 shs
Average Volume
459,481 shs
Market Capitalization
$523.48 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
1.09
30 days | 90 days | 365 days | Advanced Chart
Receive AVDL News and Ratings via Email

Sign-up to receive the latest news and ratings for Avadel Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.


Avadel Pharmaceuticals logo

About Avadel Pharmaceuticals

Avadel Pharmaceuticals Plc engages in the development and commercialization of pharmaceutical products. Its products include Bloxiverz, Vazculep, Nouress, and Akovaz. It focuses on approval of FT218, a formulation of sodium oxybate designed to treat excessive daytime sleepiness and cataplexy in adults with narcolepsy. The company was founded 1990 and is headquartered in Dublin, Ireland.

Headlines

Avadel Pharmaceuticals (NASDAQ:AVDL) Sets New 1-Year High at $11.57
November 15, 2021 |  americanbankingnews.com
See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:AVDL
Employees
2,020
Year Founded
2015

Sales & Book Value

Annual Sales
$22.33 million
Book Value
$2.78 per share

Profitability

Net Income
$7.03 million
Pretax Margin
-106.62%

Debt

Price-To-Earnings

Miscellaneous

Free Float
57,278,000
Market Cap
$523.48 million
Optionable
Optionable

Company Calendar

Last Earnings
11/08/2021
Today
12/01/2021
Fiscal Year End
12/31/2021
Next Earnings (Estimated)
3/08/2022

Social Links


MarketRank

Overall MarketRank

1.87 out of 5 stars

Medical Sector

736th out of 1,390 stocks

Pharmaceutical Preparations Industry

347th out of 669 stocks

Analyst Opinion: 3.5Community Rank: 4.4Dividend Strength: 0.0Insider Behavior: 0.8Valuation: 0.6 5 -4 -3 -2 -1 -












Avadel Pharmaceuticals (NASDAQ:AVDL) Frequently Asked Questions

Is Avadel Pharmaceuticals a buy right now?

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Avadel Pharmaceuticals in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Avadel Pharmaceuticals stock.
View analyst ratings for Avadel Pharmaceuticals
or view top-rated stocks.

How has Avadel Pharmaceuticals' stock price been impacted by COVID-19 (Coronavirus)?

Avadel Pharmaceuticals' stock was trading at $7.99 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, AVDL shares have increased by 11.8% and is now trading at $8.93.
View which stocks have been most impacted by COVID-19
.

Are investors shorting Avadel Pharmaceuticals?

Avadel Pharmaceuticals saw a increase in short interest in the month of November. As of November 15th, there was short interest totaling 4,780,000 shares, an increase of 29.9% from the October 31st total of 3,680,000 shares. Based on an average daily volume of 704,400 shares, the days-to-cover ratio is currently 6.8 days. Currently, 9.4% of the company's stock are sold short.
View Avadel Pharmaceuticals' Short Interest
.

When is Avadel Pharmaceuticals' next earnings date?

Avadel Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Tuesday, March 8th 2022.
View our earnings forecast for Avadel Pharmaceuticals
.

How were Avadel Pharmaceuticals' earnings last quarter?

Avadel Pharmaceuticals plc (NASDAQ:AVDL) posted its quarterly earnings results on Monday, November, 8th. The company reported ($0.38) earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of ($0.38). During the same quarter in the previous year, the company posted ($0.20) earnings per share.
View Avadel Pharmaceuticals' earnings history
.

What price target have analysts set for AVDL?

3 equities research analysts have issued 1 year price objectives for Avadel Pharmaceuticals' shares. Their forecasts range from $16.00 to $17.00. On average, they expect Avadel Pharmaceuticals' share price to reach $16.50 in the next year. This suggests a possible upside of 84.8% from the stock's current price.
View analysts' price targets for Avadel Pharmaceuticals
or view top-rated stocks among Wall Street analysts.

Who are Avadel Pharmaceuticals' key executives?

Avadel Pharmaceuticals' management team includes the following people:
  • Gregory J. Divis, Chief Executive Officer & Director
  • Thomas S. McHugh, Chief Financial & Accounting Officer
  • Jennifer Gudeman, Vice President-Medical & Clinical Affairs
  • Dhiren D'silva, Vice President-Irish & European Operations
  • Jason Vaughn, Senior Vice President-Technical Operations

What other stocks do shareholders of Avadel Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Avadel Pharmaceuticals investors own include Intelsat (I), Bank of America (BAC), Fossil Group (FOSL), Ciena (CIEN), AMC Entertainment (AMC), Chaarat Gold (CGH), Associated British Foods (ABF), Apollo Global Management (APO), Amarin (AMRN) and Cypress Semiconductor (CY).

What is Avadel Pharmaceuticals' stock symbol?

Avadel Pharmaceuticals trades on the NASDAQ under the ticker symbol "AVDL."

Who are Avadel Pharmaceuticals' major shareholders?

Avadel Pharmaceuticals' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Cowen AND Company LLC (4.31%), Gendell Jeffrey L (3.51%), Renaissance Technologies LLC (1.46%), Janus Henderson Group PLC (1.38%), Asymmetry Capital Management L.P. (0.81%) and Morgan Stanley (0.72%). Company insiders that own Avadel Pharmaceuticals stock include Eric J Ende, Gregory J Divis, Linda Palczuk, Mark Anthony Mccamish, Sandra L Hatten and Thomas S Mchugh.
View institutional ownership trends for Avadel Pharmaceuticals
.

Which major investors are selling Avadel Pharmaceuticals stock?

AVDL stock was sold by a variety of institutional investors in the last quarter, including Iridian Asset Management LLC CT, Tri Locum Partners LP, Deutsche Bank AG, Keel Point LLC, Citadel Advisors LLC, Renaissance Technologies LLC, Atom Investors LP, and Eaton Vance Management.
View insider buying and selling activity for Avadel Pharmaceuticals
or view top insider-selling stocks.

Which major investors are buying Avadel Pharmaceuticals stock?

AVDL stock was bought by a variety of institutional investors in the last quarter, including BioImpact Capital LLC, Asymmetry Capital Management L.P., Janus Henderson Group PLC, Morgan Stanley, Cowen AND Company LLC, Gendell Jeffrey L, Citigroup Inc., and Cubist Systematic Strategies LLC. Company insiders that have bought Avadel Pharmaceuticals stock in the last two years include Eric J Ende, Gregory J Divis, Linda Palczuk, Mark Anthony Mccamish, and Thomas S Mchugh.
View insider buying and selling activity for Avadel Pharmaceuticals
or or view top insider-buying stocks.

How do I buy shares of Avadel Pharmaceuticals?

Shares of AVDL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Avadel Pharmaceuticals' stock price today?

One share of AVDL stock can currently be purchased for approximately $8.93.

How much money does Avadel Pharmaceuticals make?

Avadel Pharmaceuticals has a market capitalization of $523.48 million and generates $22.33 million in revenue each year. The company earns $7.03 million in net income (profit) each year or ($1.13) on an earnings per share basis.

How many employees does Avadel Pharmaceuticals have?

Avadel Pharmaceuticals employs 2,020 workers across the globe.

When was Avadel Pharmaceuticals founded?

Avadel Pharmaceuticals was founded in 2015.

What is Avadel Pharmaceuticals' official website?

The official website for Avadel Pharmaceuticals is www.avadel.com.

Where are Avadel Pharmaceuticals' headquarters?

Avadel Pharmaceuticals is headquartered at 10 EARLSFORT TERRACE, DUBLIN L2, D02.

How can I contact Avadel Pharmaceuticals?

Avadel Pharmaceuticals' mailing address is 10 EARLSFORT TERRACE, DUBLIN L2, D02. The company can be reached via phone at (531) 485-1200, via email at [email protected], or via fax at 353-1526-1077.


This page was last updated on 12/1/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.